Business
Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease
VANCOUVER--(BUSINESS WIRE)-- Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel
About this update from Alpha Cognition Inc.
[{"type":"text","content":" VANCOUVER--(BUSINESS WIRE)--\nAlpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent titled “Coated Tablets for pH-Dependent Release of Benzgalantamine.”\n\n\nThis newly issued patent strengthens Alpha Cognition’s intellectual property portfolio by covering the composition of tablet formulations of benzgalantamine, further reinforcing the Company’s existing patent protections. With this approval, ZUNVEYL has patent protection in the United States through 2044, supporting the Company’s long-term growth strategy as it prepares for commercialization.\n\n\n“This patent approval underscores the innovative nature of ZUNVEYL and enhances our ability to deliver a differentiated treatment option for patients with mild to moderate Alzheimer’s disease,” said Michael McFadden, CEO of Alpha Cognition. “The timing of this milestone is significant, as it coincides with our planned U.S. launch of ZUNVEYL this quarter. With extended patent protection, we are well-positioned to maximize the potential of ZUNVEYL and continue advancing solutions for those affected by Alzheimer’s.”\n\n\nZUNVEYL represents a novel approach to symptomatic Alzheimer’s treatment, designed to improve patient outcomes through optimized drug delivery. ZUNVEYL will be available by prescription in pharmacies nationwide in Q1 2025.\n\n\nAbout Alpha Cognition Inc.\n\n\nAlpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.\n\n\nFor more information, please visit www.alphacognition.com.\n\n\nForward-looking Statements\n\n\nThis news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors ...